# Your Single Provider for **Treatment Response Monitoring**





- 1. Powles, T. et al. Molecular residual disease detection with a tissue CGP informed personalized monitoring assay: an exploratory analysis of the IMvigor010 observation arm. ASCO GU. Feb 2022
- 2. Kansara, M. et al. Molecular Oncology. 2022. https://doi.org/10.1002/1878-0261.13349
- 3. For Research Use Only. Not for use in diagnostic procedures.
- 4. For Investigational Use Only. The performance characteristics of this product have not been established.



## FOUNDATIONONE®MONITOR

#### BLOOD ONLY/TISSUE-NAÏVE

### **Test Features**



#### **Evaluates changes in ctDNA levels over time** to complement standard imaging in early-phase clinical research



#### Monitor individual variants or assess resistance to therapy across more than 300 genes



#### **Quantify ctDNA Tumor Fraction**

(TF), a biomarker that incorporates multi-omic information to improve sensitivity and maintain high specificity to monitor ctDNA levels

#### Serial ctDNA Testing Can Identify Treatment-Demonstrated Activity Across Different Doses<sup>1</sup>



■ 25 mg ■ 50 mg ■ 100 mg ■ 200 mg ■ 400 mg

Retrospective Assessment of ctDNA Tumor Fraction (TF) at a Pre-Treatment Timepoint Can Stratify Subjects for Response<sup>2</sup>



FoundationOne Monitor is **now available for research use** to add **molecular response insights** to your **retrospective studies**.

FoundationOne Monitor is based on the Foundation Medicine liquid platform.

- 1. Shum E, et al. Abstract presented at AACR 2022. Abstract CT184.
- 2. Reichert, Z.R., et al. Annals of Oncology. 2022. DOI: https://doi.org/10.1016/j.annonc.2022.09.163.

For Research Use Only. Not for use in diagnostic procedures.

FOUNDATION MEDICINE®